Skip to content

A phase 2 study of E6005 in patients with atopic dermatitis

A phase 2 study of E6005 in patients with atopic dermatitis

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221633
Enrollment
75
Registered
2011-11-01
Start date
2011-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Sponsors

Eisai Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Adults of both genders aged 20 to 64 years at the time when the written informed consent is obtained - Outpatients diagnosed with atopic dermatitis

Exclusion criteria

Exclusion criteria: - Patients with a present illness of Kaposi's varicelliform eruption, scabies, molluscum contagiosum, impetigo contagious, psoriasis, connective tissue disorder, collagen disorder or Netherton's syndrome, etc., which could have an effect on the pathological evaluation of the atopic dermatitis. - Patients with active infection that requires oral or intravenous administration of antibiotics, antifungal or antivirus agent/s at baseline. - Patients with advanced disease or abnormal laboratory tests that would possibly affect the safety of the subject or the implementation of this study.

Design outcomes

Primary

MeasureTime frame
- Assessment of safety parameters: number and variety of adverse events, clinical laboratory test - Assessment of efficacy variable: Pruritus score, area and severity of eczema

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026